These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22584507)

  • 1. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
    Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
    Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognoses of GEP-NETS with undetermined malignant potentials of their primary sites.
    Kudo A; Ban D; Akashi T; Kumagai J; Aihara A; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
    Hepatogastroenterology; 2012 Sep; 59(118):1682-6. PubMed ID: 22584425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
    Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
    Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and prognostic factors of gastroenteropancreatic neuroendocrine tumors: a single center experience in China.
    Hu HK; Ke NW; Li A; Du XJ; Guo Q; Hu WM
    Hepatogastroenterology; 2015; 62(137):178-83. PubMed ID: 25911892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.
    Strosberg JR; Weber JM; Feldman M; Coppola D; Meredith K; Kvols LK
    J Clin Oncol; 2013 Feb; 31(4):420-5. PubMed ID: 23248248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
    Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
    J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
    J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
    Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.